reactiv
oxygen
speci
ro
implic
pathogenesi
mani
diseas
human
immunodefici
viru
infect
although
ro
function
benefici
compon
immun
respons
unregul
excess
ro
toxic
caus
irrepar
damag
cellular
membran
protein
nucleic
acid
normal
physiolog
condit
antioxid
enzym
help
maintain
balanc
ro
function
interact
led
interest
gener
antioxid
therapeut
agent
rosmedi
injuri
diseas
accord
global
estim
gener
world
health
organ
million
case
pneumonia
diagnos
everi
year
approxim
million
case
end
death
account
total
mortal
worldwid
recent
emerg
sever
acut
respiratori
syndrom
sar
associ
coronaviru
avian
influenza
viru
pandem
influenza
viru
novel
avian
influenza
viru
serv
highlight
respiratori
virus
import
caus
agent
sever
pneumonia
nonetheless
current
batteri
antivir
avail
clinic
practic
treatment
pneumonia
limit
continu
pandem
threat
circul
virus
make
identif
develop
novel
therapeut
strategi
especi
treatment
influenza
urgent
matter
recent
evid
suggest
much
acut
lung
injuri
caus
attribut
excess
ro
product
ie
oxid
stress
initi
overact
innat
immun
respons
ro
includ
superoxid
anion
hydrogen
peroxid
hydroxyl
radic
indiscrimin
toxic
cell
produc
excess
capabl
regul
proinflammatori
cytokin
product
major
cellular
sourc
ro
infect
infiltr
inflammatori
cell
identif
enzymat
sourc
ro
may
pave
way
therapi
combat
oxid
stressdepend
lung
injuri
caus
influenza
viru
catalas
cat
one
key
antioxid
enzym
mammalian
system
cat
work
catalyz
decomposit
molecular
oxygen
water
play
import
role
develop
toler
oxid
stress
process
protect
sever
patholog
condit
potenti
cat
therapeut
agent
explor
mani
differ
diseas
mani
differ
form
includ
gene
therapi
recombin
cat
well
decad
previou
studi
found
inhal
nativ
pegyl
recombin
human
catalas
rhcat
elicit
protect
effect
mice
influenzaassoci
pneumonia
howev
remain
determin
rhcat
influenc
innat
immun
respons
control
clear
influenza
viru
inflammatori
cytokin
andor
possibl
inflamm
signal
pathway
present
studi
show
rhcat
novel
potenti
altern
control
influenza
infect
may
way
control
futur
pandem
modul
host
instead
viru
imprint
control
region
icr
male
mice
g
purchas
shanghai
slacca
laboratori
anim
co
ltd
shanghai
china
mice
hous
specif
pathogenfre
condit
given
free
access
steril
water
standard
mous
chow
experiment
protocol
approv
anim
experi
committe
fudan
univers
shanghai
china
influenza
viru
use
studi
highli
virul
mouseadapt
viru
isol
patient
fort
monmouth
nj
usa
outbreak
caus
sever
pneumonia
high
mortal
mice
viru
suppli
shanghai
center
diseas
control
prevent
shanghai
china
store
aliquot
experi
aliquot
thaw
ensur
use
fresh
prepar
mice
randomli
divid
group
virusinfect
rhcattreat
kukg
virusinfect
salinetr
control
viru
control
uninfect
salinetr
control
normal
control
mice
isofluran
anesthesia
infect
intranas
influenza
viru
two
hour
postinfect
mice
intranas
inocul
either
nacl
salin
rhcat
dissolv
salin
twice
daili
rhcat
obtain
accord
publish
method
surviv
studi
n
mice
per
group
treatment
administ
describ
day
mice
continu
monitor
surviv
next
day
surviv
analysi
curv
gener
plot
number
survivor
divid
total
number
mice
group
express
percentag
mice
surviv
mice
also
monitor
bodi
weight
loss
day
postinfect
histopatholog
experiment
infect
describ
perform
day
postinfect
remain
mice
n
per
group
euthan
weigh
lung
tissu
harvest
weigh
correspond
lungbodi
index
calcul
left
lobe
lung
suspend
pbsbuffer
formalin
preserv
paraffin
block
use
standard
procedur
tissu
section
cut
place
glass
slide
stain
hematoxylin
eosin
use
standard
techniqu
microscop
analysi
carri
three
separ
pathologist
blind
variou
experiment
treatment
antioxid
statu
analysi
mous
lung
homogen
mg
lobe
lung
day
freshli
prepar
dilut
ml
pb
solut
total
protein
content
malondialdehyd
mda
concentr
total
antioxid
statu
ta
superoxid
dismutas
sod
concentr
cat
concentr
determin
use
commerci
avail
assay
kit
kit
respect
jiancheng
bioengin
institut
china
cellular
analysi
inflammatori
cytokin
measur
signal
pathway
analysi
experiment
infect
describ
perform
mice
receiv
kukg
dosag
rhcat
day
postinfect
mice
n
per
group
euthan
lung
harvest
pbsperfus
mice
dice
use
surgic
scissor
dice
tissu
suspend
ml
cdti
buffer
mgml
collagenas
clostridium
histolyticum
type
iv
sigma
uml
dnase
sigma
mgml
trypsin
inhibitor
type
ii
sigma
dmem
h
suspens
pass
filter
unwant
red
blood
cell
lyse
use
red
blood
cell
lysi
buffer
ph
inflammatori
cell
purifi
centrifug
pbsbuffer
percol
ge
healthcar
life
scienc
g
min
cell
pellet
resuspend
stain
buffer
medium
fc
receptor
block
use
antimous
bd
bioscienc
cell
stain
fluoresc
label
antibodi
follow
mous
protein
neutrophil
macrophagemonocyt
tissu
concentr
murin
cytokin
intercellular
adhes
determin
use
commerci
elisa
kit
bd
bioscienc
follow
manufactur
instruct
isol
total
rna
cdna
synthesi
perform
use
trizol
reagent
invitrogen
rt
reagent
kit
takara
accord
manufactur
recommend
rt
primer
gapdh
follow
forward
revers
forward
revers
forward
revers
gapdh
forward
gapdh
revers
use
cdna
templat
quantit
realtim
pcr
carri
use
sybr
green
pcr
master
mix
appli
biosystem
stepon
plu
realtim
pcr
detect
system
appli
biosystem
accord
manufactur
instruct
follow
thermocycl
paramet
min
follow
cycl
final
melt
curv
analysi
mrna
express
level
normal
correspond
express
level
gapdh
housekeep
gene
statist
analys
perform
use
graphpad
prism
window
version
gehanbreslowwilcoxon
test
use
analyz
surviv
mice
oneway
anova
use
analyz
experiment
data
case
probabl
level
less
p
taken
indic
statist
signific
mice
treat
either
salin
rhcat
intranas
h
intranas
infect
mouseadapt
human
influenza
viru
rhcat
administr
significantli
dosedepend
manner
lengthen
surviv
time
mice
compar
viru
control
mice
fig
recipi
salin
alon
mice
viru
control
group
surviv
beyond
day
postinfect
wherea
mice
receiv
rhcat
ku
surviv
day
postinfect
p
mice
treat
rhcat
bodi
weight
loss
also
reduc
dosedepend
manner
measur
day
postinfect
p
fig
lungbodi
index
fig
total
protein
content
lung
tissu
fig
demonstr
viru
infect
caus
lung
tissu
swell
product
signific
amount
protein
exud
control
mice
rhcat
administr
ku
significantli
allevi
effect
histopatholog
analysi
lung
infect
mice
treat
rhcat
reveal
markedli
reduc
tissu
injuri
mononuclear
cell
accumul
hemorrhag
pulmonari
edema
compar
viru
control
mice
day
postinfect
fig
viral
replic
induc
excess
oxid
respons
therebi
exhaust
antioxid
pool
reason
level
key
antioxid
enzym
eg
cat
superoxid
dismutas
sod
total
antioxid
statu
ta
mda
product
lipid
peroxid
repres
rosmedi
tissu
peroxid
injuri
evalu
lung
tissu
day
postinfect
influenza
infect
induc
signific
increas
mda
decreas
cat
sod
activ
viru
control
mice
administr
rhcat
result
dosedepend
reduct
mda
higher
activ
cat
sod
fig
p
rhcat
treatment
slightli
influenc
level
ta
reveal
signific
differ
viru
control
rhcattreat
mice
fig
antioxid
system
compris
nonenzymat
antioxid
molecul
eg
vitamin
c
e
glutathion
etc
antioxid
enzym
eg
cat
sod
variou
peroxidas
therefor
reflect
ta
measur
therefor
indic
rhcat
may
partli
restor
antioxid
enzym
system
time
significantli
influenc
ta
level
thu
rhcat
administr
reduc
rosmedi
injuri
might
relev
allevi
effect
viral
pneumonia
therebi
reduc
mortal
conclus
rhcat
protect
influenza
viru
infect
dosedepend
manner
thu
kukg
rhcat
use
explor
possibl
protect
mechan
rhcat
influenza
viru
infect
robust
innat
proinflammatori
cytokin
express
caus
direct
tissu
insult
recruit
potenti
tissuedestruct
inflammatori
cell
lung
tissu
insult
high
inflammatori
cell
infiltr
observ
histopatholog
analysi
analysi
neutrophil
macrophagesmonocyt
also
reveal
signific
reduct
accumul
neutrophil
macrophagemonocyt
lung
day
postinfect
fig
analysi
cytokin
rhcattreat
mice
reveal
signific
reduct
fourth
day
postinfect
compar
control
mice
fig
c
immun
cell
infiltr
activ
affect
reduct
cytokin
product
rhcattreat
mice
also
analyz
proinflammatori
cytokin
signal
pathway
virusinfect
mice
qpcr
result
show
infect
significantli
upregul
specif
influenza
recognit
receptor
transcript
level
control
mice
treatment
rhcat
inhibit
express
interestingli
mrna
level
typic
lipopolysaccharid
lp
recognit
receptor
dramat
increas
virusinfect
mice
also
inhibit
rhcat
fig
indic
rhcat
downregul
signal
pathway
suppress
inflamm
respons
induc
infect
lethal
influenza
infect
sever
viral
pneumonia
result
high
morbid
mortal
like
due
excess
product
ro
aberr
cytokin
studi
infect
induc
signific
product
mda
caus
obviou
reduct
key
antioxid
enzym
cat
sod
indirectli
result
excess
ro
product
virusinfect
mice
administr
rhcat
significantli
inhibit
mda
product
increas
cat
sod
level
fig
suggest
rhcat
administr
partial
diminish
excess
ro
product
protect
lung
damag
aberr
excess
cytokin
product
correl
morbid
mortal
macaqu
human
infect
highli
virul
influenza
virus
mous
model
demonstr
mani
cytokin
essenti
control
viru
replic
also
exacerb
morbid
tissu
injuri
activ
inflammatori
cell
stimul
express
multipl
cytokin
chemokin
express
directli
link
host
morbid
secret
enhanc
pulmonari
injuri
administr
rhcat
result
signific
reduct
cytokin
influenza
virusinfect
mice
fig
possibl
due
downregul
nfkb
transcript
level
signal
pathway
fig
mechan
action
rhcat
block
cytokineschemokin
well
block
infiltr
activ
inflammatori
cell
cours
influenza
viru
infect
result
diminish
immunemedi
tissu
injuri
increas
surviv
mice
second
messeng
molecul
ro
also
play
key
role
inflamm
reaction
induc
virus
present
work
inflammatori
cytokin
chemokin
transcript
level
key
gene
signal
pathway
significantli
upregul
lung
tissu
mice
think
robust
ro
reaction
induc
infect
may
activ
signal
pathway
stimul
secret
associ
cytokin
result
sever
pneumonia
accompani
robust
infiltr
inflammationrel
cell
control
mice
assumpt
echo
latest
find
oxid
phospholipid
potent
stimul
inflamm
administr
rhcat
markedli
suppress
inflammatori
respons
probabl
ascrib
decreas
ro
level
direct
experi
need
futur
studi
still
mani
aspect
studi
need
investig
possibl
influenc
rhcat
murin
immun
system
innat
antioxid
enzym
transcript
level
cellular
respons
eg
autophagi
apoptosi
summari
administr
rhcat
provid
altern
effect
mechan
compar
antivir
drug
envisag
use
rhcat
combin
antivir
strategi
may
effect
tool
morbid
mortal
induc
season
pandem
strain
influenza
viru
